List of Excipients in API human immunoglobulin g
✉ Email this page to a colleague
Detailed excipient profiles for human immunoglobulin g
Excipient focus: ACETATE ION
human immunoglobulin g drug variants containing ACETATE ION
| Company | Ingredient | NDC |
|---|---|---|
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8235 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing ACETATE ION
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| >Company | >Ingredient | >NDC |
Excipient focus: ALBUMIN HUMAN
human immunoglobulin g drug variants containing ALBUMIN HUMAN
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing ALBUMIN HUMAN
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCINE
human immunoglobulin g drug variants containing GLYCINE
| Company | Ingredient | NDC |
|---|---|---|
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8235 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing GLYCINE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| >Company | >Ingredient | >NDC |
Excipient focus: HUMAN IMMUNOGLOBULIN A
human immunoglobulin g drug variants containing HUMAN IMMUNOGLOBULIN A
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing HUMAN IMMUNOGLOBULIN A
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
human immunoglobulin g drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8235 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROLINE
human immunoglobulin g drug variants containing PROLINE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing PROLINE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM ACETATE
human immunoglobulin g drug variants containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
human immunoglobulin g drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8235 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
human immunoglobulin g drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
human immunoglobulin g drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
human immunoglobulin g drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| GC Biopharma Corp | human immunoglobulin g | 61476-104 |
| KEDRION BIOPHARMA INC | human immunoglobulin g | 76125-918 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| Bio Products Laboratory Limited | human immunoglobulin g | 64208-8234 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER O-18
human immunoglobulin g drug variants containing WATER O-18
| Company | Ingredient | NDC |
|---|---|---|
| ADMA Biologics Inc | human immunoglobulin g | 69800-0250 |
| >Company | >Ingredient | >NDC |
human immunoglobulin g drug variants not containing WATER O-18
| Company | Ingredient | NDC |
|---|---|---|
| CSL Behring AG | human immunoglobulin g | 44206-417 |
| CSL Behring AG | human immunoglobulin g | 44206-436 |
| CSL Behring AG | human immunoglobulin g | 44206-451 |
| ADMA Biologics Inc | human immunoglobulin g | 59730-6502 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
